DK1663958T3 - Haloalkylholdige forbindelser som cysteinproteasehæmmere - Google Patents

Haloalkylholdige forbindelser som cysteinproteasehæmmere Download PDF

Info

Publication number
DK1663958T3
DK1663958T3 DK04784332.1T DK04784332T DK1663958T3 DK 1663958 T3 DK1663958 T3 DK 1663958T3 DK 04784332 T DK04784332 T DK 04784332T DK 1663958 T3 DK1663958 T3 DK 1663958T3
Authority
DK
Denmark
Prior art keywords
haloal
protease inhibitors
cooling compounds
cystein protease
cystein
Prior art date
Application number
DK04784332.1T
Other languages
English (en)
Inventor
John O Link
Craig J Mossman
Soon H Woo
Sheila M Zipfel
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Application granted granted Critical
Publication of DK1663958T3 publication Critical patent/DK1663958T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04784332.1T 2003-09-18 2004-09-17 Haloalkylholdige forbindelser som cysteinproteasehæmmere DK1663958T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50468003P 2003-09-18 2003-09-18
US56106204P 2004-04-09 2004-04-09
PCT/US2004/030442 WO2005028429A2 (en) 2003-09-18 2004-09-17 Haloalkyl containing compounds as cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
DK1663958T3 true DK1663958T3 (da) 2015-04-07

Family

ID=34381124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04784332.1T DK1663958T3 (da) 2003-09-18 2004-09-17 Haloalkylholdige forbindelser som cysteinproteasehæmmere

Country Status (19)

Country Link
US (1) US7547701B2 (da)
EP (1) EP1663958B1 (da)
JP (1) JP4991295B2 (da)
KR (1) KR20060079143A (da)
AU (1) AU2004274471A1 (da)
BR (1) BRPI0410979A (da)
CA (1) CA2521811A1 (da)
DK (1) DK1663958T3 (da)
EA (1) EA011855B1 (da)
ES (1) ES2534222T3 (da)
LV (1) LV13440B (da)
MX (1) MXPA05012129A (da)
NO (1) NO20061627L (da)
NZ (1) NZ542865A (da)
PT (1) PT1663958E (da)
RU (1) RU2007114127A (da)
SG (1) SG146658A1 (da)
TW (1) TW200524851A (da)
WO (1) WO2005028429A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375134B2 (en) * 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
BRPI0410979A (pt) 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
US20070141059A1 (en) * 2003-12-11 2007-06-21 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
EP1697355A2 (en) * 2003-12-23 2006-09-06 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
JP2007519744A (ja) * 2004-01-30 2007-07-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト システインプロテアーゼインヒビターとしてのシリナン化合物。
CA2580219A1 (en) * 2004-09-17 2006-03-30 Schering Aktiengesellschaft Polymorphs of the cysteine protease inhibitor n-(1-cyanocyclopropyl)-3-cyclopropylmethanesulfonyl-2(r)-(2,2,2-trifluoro-1(s)-(4-fluorophenyl) ethylamino)propionamide
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
JP4988589B2 (ja) * 2004-12-01 2012-08-01 ビロベイ，インコーポレイティド システインプロテアーゼインヒビターとしてのハロアルキル含有化合物
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
NZ561681A (en) * 2005-03-21 2011-01-28 Virobay Inc Alpha ketoamide compounds as cysteine protease inhibitors
JP5215167B2 (ja) * 2005-03-22 2013-06-19 ビロベイ，インコーポレイティド システインプロテアーゼ阻害剤としてのスルホニル基含有化合物
EP1891003A4 (en) 2005-06-02 2010-07-21 Merck Frosst Canada Ltd FLUORALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS
GB0611654D0 (en) * 2006-06-13 2006-07-19 Medivir Ab Compounds
EP2064178A4 (en) * 2006-09-08 2011-10-05 Merck Canada Inc CATHEPSIN S INHIBITOR PRODRUGS
US20100048717A1 (en) 2006-09-25 2010-02-25 MERCK FROSST CANADA LTD, Merk & Co., Inc. Cathepsin b inhibitors
DK2079683T3 (da) * 2006-10-04 2015-04-27 Virobay Inc Di-fluorholdige forbindelser som cysteinproteasehæmmere
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
JP5497732B2 (ja) * 2008-04-01 2014-05-21 ビロベイ，インコーポレイティド システインプロテアーゼ阻害剤としてのジフルオロ含有化合物
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
WO2010069069A1 (en) * 2008-12-17 2010-06-24 Merck Frosst Canada Ltd. Cathepsin b inhibitors
US20120101053A1 (en) * 2009-06-22 2012-04-26 Cameron Black Cathepsin cysteine protease inhibitors for the treatment of various diseases
US8324417B2 (en) * 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US20130331597A1 (en) * 2011-03-02 2013-12-12 Guy Humphrey Amidation process
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
CA2830117C (en) 2011-03-18 2019-04-30 Bayer Intellectual Property Gmbh N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
WO2017036357A1 (zh) 2015-08-29 2017-03-09 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
CA2306313C (en) 1997-11-05 2010-03-09 Novartis Ag Dipeptide nitriles
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
TR200103390T2 (tr) 1999-03-15 2002-05-21 Axys Pharmaceuticals, Inc. Proteaz inhibitörleri olan yeni bileşikler ve terkipler.
DE60003702T2 (de) 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2384974A1 (en) * 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Compounds and pharmaceutical compositions as cathepsin s inhibitors
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
AU2001245764A1 (en) * 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
SE521652C2 (sv) 2001-03-15 2003-11-25 Canag Diagnostics Ab En skivepitelcellcancerrelaterad fusionsgen och motsvarande fusionsprotein
CA2448418A1 (en) 2001-06-01 2002-12-12 Axys Pharmaceuticals, Inc. Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
US6936606B2 (en) 2001-10-02 2005-08-30 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
EP1446115B1 (en) * 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
US7375134B2 (en) * 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
WO2003097617A1 (en) 2002-05-14 2003-11-27 Axys Pharmaceuticals, Inc. Cysteine protease inhibitors
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
JP2006504719A (ja) 2002-10-08 2006-02-09 メルク フロスト カナダ アンド カンパニー 骨粗しょう症の治療において有用なカテプシンｋ阻害剤としての４−アミノ−アゼパン−３−オン化合物
US7326719B2 (en) 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
JP2007503401A (ja) 2003-08-27 2007-02-22 メルク フロスト カナダ リミテツド カテプシン阻害剤
BRPI0410979A (pt) 2003-09-18 2006-07-04 Axys Pharm Inc composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
EP1664003A1 (en) 2003-09-18 2006-06-07 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
PT1667975E (pt) 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
US20070141059A1 (en) 2003-12-11 2007-06-21 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
EP1697355A2 (en) 2003-12-23 2006-09-06 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
JP2007519744A (ja) 2004-01-30 2007-07-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト システインプロテアーゼインヒビターとしてのシリナン化合物。
BRPI0515470A (pt) 2004-09-17 2008-07-22 Schering Ag processos e intermediários para preparação de inibidores de cisteìna protease
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina

Also Published As

Publication number Publication date
NZ542865A (en) 2009-04-30
US7547701B2 (en) 2009-06-16
TW200524851A (en) 2005-08-01
BRPI0410979A (pt) 2006-07-04
US20050182096A1 (en) 2005-08-18
EP1663958B1 (en) 2015-02-25
KR20060079143A (ko) 2006-07-05
SG146658A1 (en) 2008-10-30
EA011855B1 (ru) 2009-06-30
MXPA05012129A (es) 2006-02-08
WO2005028429A2 (en) 2005-03-31
WO2005028429A3 (en) 2005-05-19
AU2004274471A1 (en) 2005-03-31
EP1663958A2 (en) 2006-06-07
LV13440B (en) 2006-10-20
CA2521811A1 (en) 2005-03-31
JP2007505920A (ja) 2007-03-15
JP4991295B2 (ja) 2012-08-01
EA200600588A1 (ru) 2006-08-25
RU2007114127A (ru) 2008-10-27
PT1663958E (pt) 2015-06-01
ES2534222T3 (es) 2015-04-20
NO20061627L (no) 2006-04-10

Similar Documents

Publication Publication Date Title
DK1663958T3 (da) Haloalkylholdige forbindelser som cysteinproteasehæmmere
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
ATE461200T1 (de) Inhibitoren von cysteinprotease
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
NO20044258L (no) Cystein proteaseinhibitor
SE0502338L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
NO20051236L (no) Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
ATE530554T1 (de) Serinprotease-hemmer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
ATE482214T1 (de) Aspartylproteasehemmer
DK1817276T3 (da) Cathepsin cysteine protease inhibitors
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
ATE413395T1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitor n
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK1633712T3 (da) Seks leddede amino-amid derivater som angiogenese inhibitorer
DK1865940T3 (da) Alfaketoamidforbindelser som cysteinproteasehæmmere